Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-23T04:05:34.309Z Has data issue: false hasContentIssue false

Chapter 19 - Immunohistochemistry and Flow Cytometry in Bone Marrow Haematopathology

Published online by Cambridge University Press:  12 November 2020

Jon van der Walt ,
Attilio Orazi  and
Daniel A. Arber
By
Anna Porwit  and
Mats Ehinger
Jon van der Walt
Affiliation:
St Thomas’ Hospital, London
Attilio Orazi
Affiliation:
Texas Tech University
Daniel A. Arber
Affiliation:
University of Chicago
Get access

Summary

Immunophenotyping is an important part of the integrated haematopathologic diagnostics of bone marrow (BM) samples. Integrated diagnosis should include clinical information, peripheral blood (PB) and BM smear cytology, flow cytometry (FCM) of BM aspirate, BM trephine biopsy (BMB) morphology, BMB immunohistochemistry (IHC) and cytogenetic/molecular genetic data if appropriate. Flow cytometry and IHC provide complementary information [1]. Immunophenotyping by FCM has the advantage of measuring high numbers of cells and the possibility to evaluate co-expression of several markers in various cell populations in a multicolour setting. Immunohistochemistry provides a possibility of in situ interpretation of morphology and immunophenotype simultaneously. Double IHC stains are possible but not widely used as of yet.

Keywords

Immunophenotypingflow cytometryimmunohistochemistrymethodologypanelsdiagnosis
Type
Chapter
Information
Diagnostic Bone Marrow Haematopathology , pp. 340 - 361
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Swerdlow, SH, Campo, E, Harris, NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edn. Lyon: IARC; 2017.Google Scholar
Tanqri, S, Vall, H, Kaplan, D, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS. Part III Analytical issues. Cyt B Clin Cytomet. 2013;84(5):291–308.Google Scholar
Mathis, S, Chapuis, N, Debord, C, et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia. 2013;27(10):1981–7.Google Scholar
Costa, ES, Pedreira, CE, Barrena, S, et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia. 2010;24(11):1927–33.Google Scholar
Jafari, K, Tierens, A, Rajab, A, et al. Visualization of cell composition and maturation in the bone marrow using 10-color flow cytometry and radar plots. Cytom B Clin Cytom. 2018;94B:219–29.Google Scholar
Borowitz, MJ, Guenther, KL, Shults, KE, Stelzer, GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol. 1993;100(5):534–40.Google Scholar
Arnoulet, C, Bene, MC, Durrieu, F, et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytom B Clin Cytom. 2010;78(1):4–10.Google Scholar
Davis, BH, Holden, JT, Bene, MC, et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytom B Clin Cytom. 2007;72 Suppl 1:S5–13.CrossRefGoogle ScholarPubMed
Davis, BH, Wood, B, Oldaker, T, Barnett, D. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS. Part I rationale and aims. Cytom B Clin Cytom. 2013;84(5):282–5.Google Scholar
Rajab, A, Porwit, A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. Cytom B Clin Cytom. 2015;88(4):253–60.Google Scholar
Macedo, A, Orfao, A, Gonzalez, M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia. 1995;9(6):993–8.Google ScholarPubMed
Porwit, A, Bene, MC. Acute leukemias of ambiguous origin. Am J Clin Pathol. 2015;144(3):361–76.Google Scholar
Kappelmayer, J, Gratama, JW, Karaszi, E, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods. 2000;242(1–2):53–65.Google Scholar
Schuurhuis, GJ, Heuser, M, Freeman, S, et al. Minimal/measurable residual disease in AML: a consensus document from European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–91.Google Scholar
Campana, D, Pui, CH. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood. 2017;129(14):1913–18.Google Scholar
Terwijn, M, Zeijlemaker, W, Kelder, A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PloS One. 2014;9(9):e107587.CrossRefGoogle Scholar
Lucio, P, Parreira, A, van den Beemd, MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia. 1999;13(3):419–27.Google Scholar
Theunissen, P, Mejstrikova, E, Sedek, L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129(3):347–57.Google Scholar
Theunissen, PMJ, Sedek, L, De Haas, V, et al. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. Br J Haematol. 2017;178(2):257–66.Google Scholar
Dworzak, MN, Froschl, G, Printz, D, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18(4):703–8.CrossRefGoogle ScholarPubMed
Campana, D, Coustan-Smith, E, Janossy, G. The immunologic detection of minimal residual disease in acute leukemia. Blood. 1990;76(1):163–71.Google Scholar
Westers, TM, Ireland, R, Kern, W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730–41.Google Scholar
Porwit, A. Is there a role for flow cytometry in the evaluation of patients with myelodysplastic syndromes? Curr Hematol Malig Rep. 2015;10(3):309–17.Google Scholar
Matarraz, S, Almeida, J, Flores-Montero, J, et al. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytom B Clin Cytom. 2017;92(3):218–27.Google Scholar
Porwit, A, Fend, F, Kremer, M, et al. Issues in diagnosis of small B cell lymphoid neoplasms involving the bone marrow and peripheral blood. Report on the Bone Marrow Workshop of the XVIIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2016;69(3):349–73.Google Scholar
Porwit, A. Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population. Int J Lab Hematol. 2013;35(3):275–82.CrossRefGoogle ScholarPubMed
Flores-Montero, J, de Tute, R, Paiva, B, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytom B Clin Cytom. 2016;90(1):61–72.Google Scholar
Stetler-Stevenson, M, Paiva, B, Stoolman, L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytom B Clin Cytom. 2016;90(1):26–30.Google Scholar
Torlakovic, EE, Naresh, K, Kremer, M, et al. Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study. J Clin Pathol. 2009;62(6):547–51.Google Scholar
Torlakovic, EE, Brynes, RK, Hyjek, E, et al. ICSH guidelines for the standardization of bone marrow immunohistochemistry. Int J Lab Hematol. 2015;37(4):431–49.Google Scholar
Torlakovic, EE, Nielsen, S, Francis, G, et al. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015;23(1):1–18.Google Scholar
Torlakovic, EE, Francis, G, Garratt, J, et al. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl Immunohistochem Mol Morphol. 2014;22(4):241–52.Google Scholar
Falini, B, Nicoletti, I, Bolli, N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519–32.Google Scholar
Fernandez-Pol, S, Ma, L, Ohgami, RS, Arber, DA. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017;30(3):382–92.Google Scholar
Valent, P, Orazi, A, Busche, G, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget. 2010;1(7):483–96.Google Scholar
Della Porta, MG, Malcovati, L, Boveri, E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–62.Google Scholar
Orazi, A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007;74(2):97–114.Google Scholar
Naresh, KN, Lampert, IA. CD117 Expression as an aid to identify immature myeloid cells and foci of ALIP in bone marrow trephines. Am J Hematol. 2006;81(1):79.Google Scholar
Saft, L, Karimi, M, Ghaderi, M, et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014;99(6):1041–9.Google Scholar
Loghavi, S, Al-Ibraheemi, A, Zuo, Z, et al. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015;171(1):91–9.Google Scholar
Lin, F, Liu, H. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Arch Pathol Lab Med. 2014;138(12):1583–610.CrossRefGoogle ScholarPubMed
Porwit, A, Rajab, A. Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of MDS-related features. Int J Lab Hematol. 2015;37 Suppl 1:133–43.CrossRefGoogle Scholar
Rajab, A, Axler, O, Leung, J, Wozniak, M, Porwit, A. Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population. Int J Lab Hematol. 2017;39 Suppl 1:76–85.Google Scholar
Collective, P. Panel proposal for the immunophenotypic diagnosis of hematological malignancies. A collaborative consensus from the groupe d’Etude Immunologique des Leucemies (GEIL). Cytom B Clin Cytom. 2018;94(3):542–7.Google Scholar
van Dongen, JJ, Lhermitte, L, Bottcher, S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–75.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×